The FDA peptides vote is days away. This insider expects approval

<p>Thanks to our partner:Superpower - https://superpower.com</p><p><br></p><p>In episode 74, Jonathan Stern sits down with Dr. Jesse Morse, a board-certified family and sports medicine physician, longtime peptide prescriber who helped assemble safety evidence for the upcoming PCAC review. They discuss the FDA briefing recommending against adding seven peptides to the 503A bulks list and how the 2023 restrictions pushed demand into gray and black markets. Morse breaks down the 7 peptides under review -- BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax -- including their proposed uses, safety concerns, and his approval odds for each. The conversation also covers peptide efficacy standards, the politics behind the FDA process, and why U.S.-made API could become a major advantage for Hims &amp; Hers.</p><p><br></p><p>00:00 - Sponsor: Superpower</p><p>01:37 - FDA briefing document </p><p>03:24 - Getting peptides back in front of the FDA</p><p>08:58 - Prescribing peptides back in 2017</p><p>12:42 - Peptides safety data</p><p>16:08 - BPC-157 deep-dive and odds for approval</p><p>22:56 - TB-500 deep-dive</p><p>26:15 - Approval odds for the other 5 peptides</p><p>31:02 - Peptide efficacy data </p><p>34:40 - FDA politics and final decisions</p><p>40:30 - Peptides market size</p><p>42:48 - Training the doctors</p><p>47:20 - Shipping hurdles and gray-market risk</p><p>53:25 - Why peptides could reshape healthcare</p><p><br></p><p>Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.</p>